Human Immunodeficiency Virus-Associated Pulmonary Arterial Hypertension
Human Immunodeficiency Virus-Associated Pulmonary Arterial Hypertension
复制标题
DOI：
10.1016/j.ccm.2013.01.009
复制
发表时间：
2013-06-01
影响因子：
5.7
通讯作者：
Hsue, Priscilla Y.
中科院分区：
文献类型：
--
作者：
Barnett, Christopher F.;Hsue, Priscilla Y.
抗逆转录病毒疗法大大延长了人类免疫缺陷病毒（HIV）感染者的寿命。约0.5%的HIV感染者会出现中度至重度肺动脉高压，比特发性肺动脉高压的发病率高几千倍。由于有3 000多万人受到慢性感染，艾滋病毒感染可能很快成为全世界肺动脉高压最常见的原因之一。肺动脉高压是一种持续进行性疾病，可导致右心衰竭和死亡。本文综述了艾滋病相关肺动脉高压的流行病学、血流动力学、发病机制和治疗策略。
Antiretroviral therapy has greatly increased longevity for individuals with human immunodeficiency virus (HIV) infection. About 0.5% of patients with HIV infection develop moderate to severe pulmonary arterial hypertension, which is several thousand times higher than the incidence of idiopathic pulmonary arterial hypertension. As more than 30 million individuals are chronically infected, HIV infection could soon become one of the most common causes of pulmonary arterial hypertension worldwide. Pulmonary arterial hypertension is a relentlessly progressive disease leading to right heart failure and death. In this article the available data on epidemiology, hemodynamics, mechanisms, and therapeutic strategies for HIV-associated pulmonary arterial hypertension are reviewed.